NuMedii

NuMedii is a medical technology company using Artificial Intelligence and Big Data to accelerate the discovery of new drugs and therapies. With the available data on genomics, molecular and biomedical data, and knowledge of drugs, the company develops various machine learning models for finding new therapeutic drugs for cancer and other diseases. The company licenses its drug candidates with pharmaceuticals for development and commercialization. As of March 2019, the company primarily works in areas related to inflammation, oncology, and rare diseases.

The company’s Artificial Intelligence technology, AIDD (Artificial Intelligence for Drug Discovery) combines public medical information and combines it with proprietary data sources to curate and normalize data to find correlations and patterns to reveal new drugs, targets, and biomarkers. The AIDD machine learning models are said to use 5 billion facts and trillions of data point relationships between medicines and diseases.

AIDD also works to provide personalized therapeutic remedies to patients by analyzing complexities of disease manifestation at the molecular and clinical levels. The AIDD can identify subsets of patients that might react better to specific therapies. Understanding the complexities of drug and identifying specific subgroups of patients through artificial intelligence reduces the guesswork related to traditional medical therapies. The company used a systematic drug repositioning bio-informatics approach on gene expression profiles to identify drugs to treat SCLC (Small Cell Lung Cancer).

The company collaborates with other companies to research and discover new medicine for specific diseases. Numedii started collaborating with John Hopkins School of Medicine in November 2018, to discover therapeutic options and drug candidates for pancreatitis.

Atul Butte, Gini Deshpande, and Joel Dudley founded NuMedii in 2008 and is headquartered in the San Francisco Bay Area.